Program
anbenitamab
Also written as “KN026”, “KN026 combination” and “Recombinant Humanized Bispecific antibody against HER2,KN026”.
Its studies are mostly in Breast Neoplasms · Stomach Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alphamab Oncology | 61 open or running | phase 2since Apr 22, 2019 | Aug 3, 2018 | none ahead |
| CSPC Pharmaceutical Group | 66 open or running | phase 3since Jun 14, 2022 | Jun 14, 2022 | Dec 16, 2026phase 3 · NCT06747338 |
- Named in CSPC Pharmaceutical Group’s own pipeline as
anbenitamab (KN026)
, phase 4, as of Aug 20, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 3, 2018First study: phase 1 study in Breast NeoplasmsNew to Alphamab OncologyAlphamab Oncology · NCT03619681 · 63 enrolled · China
- Feb 18, 2019Phase 1 study in Breast NeoplasmsAlphamab Oncology · NCT03847168 · 22 enrolled · United States
- Apr 22, 2019Phase 2 study in Gastric/Gastroesophageal Junction CancerAlphamab Oncology · NCT03925974 · 45 enrolled · China
- Nov 1, 2019Phase 2 study in Breast NeoplasmsAlphamab Oncology · NCT04165993 · 68 enrolled · China
- Aug 18, 2020Phase 2 study in HER2-positive Solid TumorsAlphamab Oncology · NCT04521179 · 102 enrolled · China
- May 6, 2021Phase 2 study in Breast NeoplasmsAlphamab Oncology · NCT04881929 · 30 enrolled · China
- Jun 14, 2022CSPC Pharmaceutical Group's first study: phase 3 study in Stomach NeoplasmsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT05427383 · 286 planned · China
- Apr 20, 2023Phase 3 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT05838066 · 880 planned · China
- Dec 13, 2024Phase 3 study in Early or Locally Advanced HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT06747338 · 520 enrolled · China
- May 12, 2025Phase 2 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT06998771 · 153 planned
- Dec 25, 2025Phase 3 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT07332533 · 490 planned
- Feb 12, 2026Phase 3 study in Resectable HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT07441460 · 1,800 planned · China
Ahead
- Dec 16, 2026Primary completion: phase 3 study in Early or Locally Advanced HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT06747338
- Jun 30, 2028Primary completion: phase 2 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT06998771
- Jun 30, 2032Primary completion: phase 3 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT07332533
- Aug 7, 2034Primary completion: phase 3 study in Resectable HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT07441460
TargetBeta
“An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HE…”NCIt, read by Claude
“An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2;”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07441460Resectable HER2-positive Breast Cancer · China | 3 | Recruiting | CSPC Pharmaceutical Group | Aug 7, 2034 | 1,800 |
| NCT07332533HER2-positive Gastric Cancer | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 30, 2032 | 490 |
| NCT06998771HER2-positive Gastric Cancer | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 30, 2028 | 153 |
| NCT06747338Early or Locally Advanced HER2-positive Breast Cancer · China | 3 | Active, not recruiting | CSPC Pharmaceutical Group | Dec 16, 2026 | 520 |
| NCT05838066Breast Neoplasms · China | 3 | Recruiting | CSPC Pharmaceutical Group | Jul 31, 2025 | 880 |
| NCT05427383Stomach Neoplasms · China | 3 | Recruiting | CSPC Pharmaceutical Group | Nov 2025 | 286 |
| NCT04881929Breast Neoplasms · China | 2 | UNKNOWN | Alphamab Oncology | Nov 15, 2022 | 30 |
| NCT04521179HER2-positive Solid Tumors · China | 2 | Completed | Alphamab Oncology | Jan 12, 2022 | 102 |
| NCT04165993Breast Neoplasms · China | 2 | Active, not recruiting | Alphamab Oncology | May 27, 2021 | 68 |
| NCT03925974Gastric/Gastroesophageal Junction Cancer · China | 2 | Completed | Alphamab Oncology | May 31, 2022 | 45 |
| NCT03847168Breast Neoplasms · United States | 1 | UNKNOWN | Alphamab Oncology | Dec 31, 2022 | 22 |
| NCT03619681Breast Neoplasms · China | 1 | Completed | Alphamab Oncology | Jun 30, 2022 | 63 |
How it is read
Names in the registry
- “KN026”, 7 entries
- “KN026 combination”, 2 entries
- “Recombinant Humanized Bispecific antibody against HER2,KN026”, 1 entry
- “KN026 10 mg/kg QW”, 1 entry
- “KN026 20 mg/kg Q2W”, 1 entry
Codes read as this program: KN026.
Conditions, from the studies’ own filings
- Breast Neoplasms, 7 studies
- Stomach Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.